Professor Deborah White

Director, Cancer Program and Deputy Theme

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Professor Deborah White PhD FFSc (RCPA)

Professor White is the Director of the Cancer Program and Deputy Precision Medicine Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI) in Adelaide. She is a NHMRC RD Wright Biomedical Research Fellow, a Beat Cancer Prinicpal Research Fellow and Senior Principal Research Fellow with SAHMRI. She is a Professor in Health and Medical Sciences at the University of Adelaide and Health Sciences at Uni SA.

Prof White’s research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL) and Chronic Myeloid Leukaemia (CML) and she holds peer reviewed grants from: The William Lawrence and Blanche Hughes Foundation and the Leukemia Lymphoma Society (USA), the NHMRC, the Leukaemia Foundation Australia (LFA), Channel 7, Cancer Australia, Tour de Cure and the Cancer Council SA (CCSA). Professor White has presented more than 170 papers at scientific meetings, and authored more than 100 scientific publications as well as being an inventor on several international patents.

Professor White is the National Flagship Lead for the ALL Stream of Australian Genomics, and SA scientific lead for Zero Children’s Cancer She is an active member of the National Health & Medical Research Council (NHMRC) being a member of the NHMRC Academy, the Translational Research Program Advisory Committee, and the Women in Health Science (WiHS) Committee. She is a member of the Editorial Board for Cancer Letters.

In 2014 she was recognised as the Australian Society for Medical Research (ASMR) Leading Light for her Medical Research and in 2016 was awarded the University of Adelaide James McWha medal. In 2019 she was awarded a prestigious NHMRC Research Excellence Award and awarded the Beat Cancer Women in Leadership Award in 2020.

My Research
Career
Publications
Grants and Funding
Teaching
Supervision
Professional Activities
Contact

Leukaemia Research Group - Precision Medicine Theme, Cancer Program, SAHMRI

Lead: Professor Deborah White

Email: deborah.white@sahmri.com

A/ RESEARCH PROJECT
Brief description of research area.

T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a genomically complex, high-risk disease affecting both children and adults. Novel, targeted treatments are urgently required to prevent drug resistance and relapse. T-ALL is characterised by recurrent gene fusions and concomitant structural abnormalities. Ongoing advances in next generation sequencing (NGS) have enabled classification of a diverse range of genomic alterations resulting in new T-ALL subtypes. Critically, the wealth of genomic information available has identified new and recurrent genomic lesions but their biological and clinical implications remain unclear. Incorporating the knowledge gained through NGS into clinical care presents a major challenge.

Currently, up to 30% of paediatric/adolescent T-ALL patients relapse with subsequent poor overall survival; the outcome is worse for adult patients with long-term survival rates after relapse below 10%. The over-arching focus of my studies is the generation of patient-derived xenograft (PDX) and transgenic mouse models of T-ALL from patient samples received in the laboratory. These models will be used to (1) examine re-purposing drugs and testing novel therapies; and (2) provide therapeutic options for pre-emptive intervention in the case of therapy-resistant disease. Central nervous system (CNS) involvement is common in relapsed ALL but drivers of this aggressive disease are poorly defined. This project will use imaging studies to track specific disease subtypes demonstrating CNS penetration.

Research Project 1 - Dr Laura Eadie

Title: Evaluation of leukaemic invasion and penetrancein mouse models of ALL.

Project description:

Our laboratory is the National Referral Centre for genomic screening of ALL cases allowing identification of genomic alterations in a large number of patients.Establishment of PDX models from these patient samples is ongoing. Recent PDXs have resulted in leukaemic engraftment within the brain, indicative of CNS involvement and suggesting an aggressive disease. CNS penetration in ALL is a significant un-met clinical need, however, the pathogenesis of CNS disease, the underlying genomic determinants and the biology driving CNS penetration remain poorly understood and targeted therapies are limited.

Additional PDX models resulted in rapid detection of leukaemic cells within the blood, but not the bone marrow or brain, highlight the complexity of individual leukaemias and the need for real-time disease imaging and tracking. Fluorescently-tagged cells harvested from PDX models or transgenic cells harbouring genomic lesions of interest will be used to investigate CNS involvement. Cells isolated from leukaemic organs will be comprehensively characterised using molecular biology and NGS approaches. Surface receptor expression profiles of leukaemic cells will be examined to determine potential causes of invasion. Computational network biology analyses will be performed to define druggable pathways. Results from this project will inform on disease invasion and allow evaluation of treatment strategies for aggressive disease phenotypes in real-time.

Projects available for: Mphil / PhD

Location: SAHMRI

Research project start: Semester 1

Special requirements: Police Clearance

Max Number of Students: 1

Category: Wet Lab

Research Area: Cancer Biology and Clinical Oncology

B/ RESEARCH PROJECT
Brief description of research area.

Acute Lymphoblastic Leukaemia (ALL) is the most common childhood cancer, and leading cause of non-traumatic death in children. For adolescents and young adults (AYA) with ALL the therapeutic outcomes are poor. Most older adults will die of their disease. The recent wealth of genomic information has seen the emergence of new lesions known to confer high-risk, and other recurrent fusions and gene deletions for which the biological and clinical implications remain unclear. Further, recent studies have implicated the human microbiome in ALL development, treatment response and life-long comorbidities. The major challenge is to incorporate knowledge gained through Next Generation Sequencing (NGS) into clinical care and to systematically identify druggabletargets and rational effective therapies to improve patient outcomes. To add to the complexity of therapeutic choice in ALL, immunotherapies (bi-specific T-cell engagers (BiTEs) and CAR-T cells), have shown efficacy in the relapsed/refractory setting, as a transplantation bridge. However, not all high-risk/relapsed ALL patients are eligible for immunotherapy, ~50% of patients experience severe hypersensitivity reactions and the long-term clinical sequelae remains unknown. Our laboratory is the National Referral Centre for genomic screening of ALL cases across all age groups, as such we sequence a large number of patients and have identified a significant number of alterations and novel gene fusions for investigation.

Research Project 2 –

Title: Cloning acute lymphoblastic leukaemia fusion genes and variants, functional characterisation and therapeutic responses.

Project description:

Recent advances in genomic profiling have defined B-cell Acute Lymphoblastic Leukeamia (B-ALL) as a heterogeneous disease with multiple subgroups characterised by distinct genetic alterations. Many genomic lesions in B-ALL are associated with alterations of cytokine receptors or their signaling pathway mediators, transcription factors or regulators of differentiation.Genomic lesions in ALL patients stratify with prognosis and using transcriptomic analysis, we have identified a number of poorly characterisedfusion genes and variants in patients. This project aims to clone full-length fusion-genes and gene variants from patient material into mammalian expression plasmids. This will allow in vitrocharacterisation in cell line models of aberrant signalling pathways that drive disease and assess therapeutic responses. This project will involve a range of molecular biology and cloning techniques including primer design, PCR Sanger sequencing, bacterial work, tissue culture and flow cytometry.

Projects available for: Third Year (Basic Science) / Honours

Location: SAHMRI

Research project start: Semester 1

Special requirements: Police Clearance

Max Number of Students: 1

Category: Wet Lab

Research Area: Cancer Biology and Clinical Oncology

Research Project 3 – Dr Sue Heatley

Title: Investigation of resistance mechanisms to the bispecific T-cell engager (BiTE) blinatumomab in relapsed acute lymphoblastic leukaemia.

Project description:

Recently, a new compound of drug known as Bispecific T-cell engager (BiTE) has been approved for use in B-ALL by the Food and Drug Administration (FDA) and is currently undergoing clinical trials in Australia. Blinatumomab is a BiTE that enables an immunological response between the CD19 positive leukaemic cell and a cytotoxic CD3 positive T-cell. While the introduction of blinatumomab promises to be an exciting addition to the clinical arsenal, initial response rates in relapsed/refractory ALL have been ~43% and, as with other treatments, resistance is likely to occur. Immune evasion is a likely cause of resistance as well as loss of the CD19 target, leading to CD19 negative relapse and further investigation is warranted.

Relapsed patient samples that are identified as being treated with blinatumomab will be flow sorted by CD19 positivity. CD19 positive and CD19 negative populations will undergo mRNAseq to identify if a lineage switch has occurred and if the driving event is now present in the CD19 negative population. Differences in gene expression will also be interrogated.

Resistance will be modelled in-vitroby subjecting fusion constructs to incrementally increasing doses of blinatumomab, enabling further examination of potential immune evasion pathways.

Projects available for: Honours / Mphil / PhD

Location: SAHMRI

Research project start: Semester 1

Special requirements: Police Clearance

Max Number of Students: 1

Category: Wet Lab

Research Area: Cancer Biology and Clinical Oncology

Appointments

Date	Position	Institution name
2017 - ongoing	Adjunct Professor Faculty of Health Sciences	University of South Australia, Adelaide
2015 - ongoing	Deputy Theme Leader (Precision Medicine) & Director of Cancer Research	South Australian Health and Medical Research Institute
2015 - ongoing	Affiliate Professor Medicine	University of Adelaide
2015 - ongoing	Affiliate Professor Paediatrics	University of Adelaide
2015 - ongoing	Affiliate Professor	University of Adelaide
2015 - ongoing	Principal Research Fellow	South Australian Health and Medical Research Institute
2015 - ongoing	Group Leader	South Australian Health and Medical Research Institute
2013 - ongoing	Affiliate Professor Pediatrics	University of Adelaide
2013 - ongoing	Affiliate Professor Medicine	University of Adelaide
2013 - ongoing	Principal Research Fellow	South Australian Health and Medical Research Institute
2013 - ongoing	Director of Cancer Research	South Australian Health and Medical Research Institute
2013 - ongoing	Director of Cancer Research	South Australian Health and Medical Research Institute, Adelaide
2013 - ongoing	Principal Research Fellow	South Australian Health and Medical Research Faculty
2013 - ongoing	Faculty Member	SA Pathology
2011 - ongoing	Head of Research	SA Pathology
2011 - ongoing	Adjunct Associate Professor	University of South Australia
2011 - ongoing	Affiliate Associate Professor Medicine	University of Adelaide
2011 - ongoing	Chief Medical Scientist and Scientific Head	University of Adelaide
2000 - ongoing	Chief Medical Technician	SA Pathology

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
2021	Award	Beat Cancer Women in Leadership Award	Cancer Council	Australia	-
2019	Fellowship	NHMRC Research Excellence Award	NHMRC	Australia	-
2017	Award	Light the Night Blue Ambassador.	Leukaemia Foundation of Australia	Australia	-
2016	Award	Shortlisted Candidate National Academy of Science Gottschalk Medal	-	-	-
2016	Award	Finalist Winnovation Award (Science and Medicine Category)	-	-	-
2016	Award	2016 James McWha Medalist	-	-	-
2014	Award	Australian Society for Medical Research (ASMR) Leading Light for 2014	-	-	-
2013	Award	2013 Abstract accepted for the Presidential Symposium	-	-	-
2012	Award	2012 Abstract accepted for the Presidential Symposium	-	-	-
2011	Recognition	Member of the Chief Investigative Team recognized by the NHMRC for one of the “Ten of the Best Project Grants”	-	Australia	-
2011	Award	Centre for Cancer Biology Prize for Highest Impact Paper 2009-2010	-	Australia	-
2009	Distinction	Hanson Centre Clinical Researcher of the Year	-	Australia	-
1994	Award	Travel Award for Outstanding Young Scientific Investigators	Health Science Alliance	Australia	-
1992	Award	Travel Award for Outstanding Young Scientific Investigators	Health Science Alliance	Australia	-
1988	Recognition	Outstanding Achievement in the field of Haematology	University of South Australia	-	-
1987	Award	Travel Award for Outstanding Young Scientific Investigators	Health Science Alliance	Australia	-

Education

Date Institution name Country Title
2011 Faculty of Science Royal College of Pathologists Australia FFSc RCPA, Founding Fellow
2008 The University of Adelaide Australia PhD
Research Interests

Cancer Biology and Clinical Oncology Translational Health Outcomes

Date	Institution name	Country	Title
2011	Faculty of Science Royal College of Pathologists	Australia	FFSc RCPA, Founding Fellow
2008	The University of Adelaide	Australia	PhD

Journals

Year	Citation
2023	Eadie, L. N., Rehn, J. A., Breen, J., Osborn, M. P., Jessop, S., Downes, C. E. J., . . . White, D. L. (2023). Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia. Genes, 14(2), 264-1-264-11. DOI
2023	Kutyna, M. M., Loone, S., Saunders, V. A., White, D. L., Kok, C. H., & Hiwase, D. K. (2023). Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. International Journal of Molecular Sciences, 24(4), 3553-1-3553-14. DOI
2023	Page, E. C., Heatley, S. L., Rehn, J., Thomas, P. Q., Yeung, D. T., & White, D. L. (2023). Gain of chromosome 21 increases the propensity for P2RY8: :CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression. Frontiers in Oncology, 13, 1177871. DOI Scopus2
2023	Eadie, L. N., Rehn, J. A., Schutz, C. E., Heatley, S. L., Kutyna, M. M., Hiwase, D. K., . . . Yeung, D. T. (2023). Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling. British Journal of Haematology, 203(2), 282-287. DOI
2023	Leow, B. C. S., Kok, C. H., Yeung, D. T., Hughes, T. P., White, D. L., & Eadie, L. N. (2023). The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism. Sci Rep, 13(1), 1-12. DOI
2023	Kok, C. H., Saunders, V. A., Dang, P., Shanmuganathan, N., White, D., Branford, S., . . . Hughes, T. P. (2023). Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib. Blood Cancer Journal, 13(1), 1-9. DOI
2023	Thomson, A. J., Rehn, J. A., Heatley, S. L., Eadie, L. N., Page, E. C., Schutz, C., . . . White, D. L. (2023). Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients. Cancers, 15(19), 1-13. DOI
2023	Nunn, J., Adayapalam, N., Riyat, S., Seymour, L., Williams, B., Rehn, J., . . . Tsuchiya, K. (2023). Paediatric B lymphoblastic leukaemia with hyperdiploidy and a false-positive KMT2A fluorescence in situ hybridization result. Cancer Genetics, 278-279, 80-83. DOI
2022	Page, E. C., Heatley, S. L., Eadie, L. N., McClure, B. J., de Bock, C. E., Omari, S., . . . White, D. L. (2022). HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort. Oncogene, 41(6), 797-808. DOI Scopus11 WoS5 Europe PMC7
2022	McClure, B. J., Pal, M., Heatley, S. L., Rehn, J., Schutz, C., Breen, J., . . . White, D. L. (2022). Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features. British Journal of Haematology, 196(6), 1407-1411. DOI Scopus2 WoS2 Europe PMC2
2022	Shirazi, P. T., Eadie, L. N., Heatley, S. L., Page, E. C., François, M., Hughes, T. P., . . . White, D. L. (2022). Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia. Cancer Gene Therapy, 29(8-9), 1140-1152. DOI Scopus4 WoS2 Europe PMC4
2022	Kimura, S., Montefiori, L., Iacobucci, I., Zhao, Y., Gao, Q., Paietta, E. M., . . . Mullighan, C. G. (2022). Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood, 139(24), 3519-3531. DOI Scopus17 WoS12 Europe PMC12
2022	Forgione, M. O., McClure, B. J., Page, E. C., Yeung, D. T., Eadie, L. N., & White, D. L. (2022). TP53 loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137.. Oncol Rep, 47(5), 1-7. DOI Scopus1 Europe PMC1
2022	Mäkinen, V. -P., Rehn, J., Breen, J., Yeung, D., & White, D. L. (2022). Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 23(9), 1-17. DOI Scopus8 WoS3 Europe PMC7
2022	Heatley, S. L., Page, E. C., Eadie, L. N., McClure, B. J., Rehn, J., Yeung, D. T., . . . White, D. L. (2022). Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis. Frontiers in Oncology, 12, 851572-1-851572-6. DOI Scopus1 WoS1 Europe PMC1
2022	Venn, N. C., Huang, L., Hovorková, L., Muskovic, W., Wong, M., Law, T., . . . Sutton, R. (2022). Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions. British Journal of Cancer, 127(5), 908-915. DOI Scopus2 Europe PMC2
2022	Downes, C. E., McClure, B. J., McDougal, D. P., Heatley, S. L., Bruning, J. B., Thomas, D., . . . White, D. L. (2022). JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. Frontiers in Cell and Developmental Biology, 10, 1-34. DOI Scopus13 WoS8 Europe PMC6
2022	Rehn, J., Mayoh, C., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C., . . . White, D. L. (2022). Rascall: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL). PLoS Genetics, 18(10), 1-23. DOI Scopus11 WoS5 Europe PMC8
2022	Downes, C. E. J., Rehn, J., Heatley, S. L., Yeung, D., McClure, B. J., & White, D. L. (2022). Identification of a novel GOLGA4–JAK2 fusion gene in B-cell acute lymphoblastic leukaemia. British Journal of Haematology, 196(3), 700-705. DOI Scopus2 WoS2 Europe PMC1
2022	Yeung, D. T. O., Osborn, M. P., & White, D. L. (2022). B‐cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification. British Journal of Haematology, 197(1), 13-27. DOI Scopus10 WoS7 Europe PMC6
2021	El Khawanky, N., Hughes, A., Yu, W., Myburgh, R., Matschulla, T., Taromi, S., . . . Zeiser, R. (2021). Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun, 12(1), 6436-1-6436-20. DOI Scopus47 WoS30 Europe PMC34
2021	Mallik, S., Yeung, D., Rehn, J., Nguyen, T., Dunlop, L., Kwan, J., & White, D. (2021). Monocytoid switch in an adult with B-cell precursor acute lymphoblastic leukaemia characterised by the PAX5 P80R mutation. Pathology, 54(5), 631-634. DOI Scopus1
2021	Blake, S. J., James, J., Ryan, F. J., Caparros-Martin, J., Eden, G. L., Tee, Y. C., . . . Lynn, D. J. (2021). The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell Reports Medicine, 2(12), 100464-1-100464-e9. DOI Scopus16 WoS10 Europe PMC15
2021	Heatley, S. L., Asari, K., Schutz, C. E., Leclercq, T. M., McClure, B. J., Eadie, L. N., . . . White, D. L. (2021). In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy. Leukemia and Lymphoma, 62(5), 1157-1166. DOI Scopus1
2021	Fitter, S., Bradey, A. L., Kok, C. H., Noll, J. E., Wilczek, V. J., Venn, N. C., . . . Revesz, T. (2021). CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre‐B‐cell acute lymphoblastic leukaemia. British Journal of Haematology, 193(1), 171-175. DOI Scopus2 WoS1 Europe PMC1
2021	Asari, K., Sun, W. T., Kok, Z. H., Lam, Y. H., Ng, B. L., Saunders, V., . . . Xiang, W. (2021). Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation. Anti-Cancer Drugs, 32(5), 526-536. DOI Scopus2 WoS1 Europe PMC1
2021	Sutton, R., Pozza, L. D., Khaw, S. L., Fraser, C., Revesz, T., Chamberlain, J., . . . Kotecha, R. S. (2021). Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. Pediatric Blood and Cancer, 68(5), 1-7. DOI Scopus16 WoS15 Europe PMC10
2021	Downes, C. E. J., McClure, B. J., Bruning, J. B., Page, E., Breen, J., Rehn, J., . . . White, D. L. (2021). Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia. NPJ Precision Oncology, 5(1), 1-13. DOI Scopus11 WoS8 Europe PMC7
2021	Tavakoli Shirazi, P., Eadie, L. N., Page, E. C., Heatley, S. L., Bruning, J. B., & White, D. L. (2021). Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia. Cancer Letters, 512, 28-37. DOI Scopus8 WoS8 Europe PMC4
2020	Irani, Y. D., Hughes, A., Clarson, J., Kok, C. H., Shanmuganathan, N., White, D. L., . . . Yong, A. S. M. (2020). Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. British Journal of Haematology, 191(3), 433-441. DOI Scopus48 WoS37 Europe PMC33
2020	Forgione, M. O., McClure, B. J., Yeung, D. T., Eadie, L. N., & White, D. L. (2020). MLLT10 rearranged acute leukemia: incidence, prognosis and possible therapeutic strategies. Genes, Chromosomes and Cancer, 59(12), 709-721. DOI Scopus8 WoS7 Europe PMC4
2020	McClure, B. J., Heatley, S. L., Rehn, J., Breen, J., Sutton, R., Hughes, T. P., . . . White, D. L. (2020). High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse. British Journal of Haematology, 191(2), 301-304. DOI Scopus2 WoS1 Europe PMC1
2020	Rehn, J. A., O'Connor, M. J., White, D. L., & Yeung, D. T. (2020). DUX hunting-clinical features and diagnostic challenges associated with DUX4-rearranged leukaemia. Cancers (Basel), 12(10), 1-15. DOI Scopus13 WoS8 Europe PMC10
2020	Schmitz, U., Shah, J. S., Dhungel, B. P., Monteuuis, G., Luu, P. -L., Petrova, V., . . . Rasko, J. E. J. (2020). Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients. Cancers, 12(12), 3738-1-3738-19. DOI Scopus9 WoS9 Europe PMC8
2020	Cario, G., Leoni, V., Conter, V., Attarbaschi, A., Zaliova, M., Sramkova, L., . . . Biondi, A. (2020). Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.. Haematologica, 105(7), 1887-1894. DOI Scopus31 WoS26 Europe PMC20
2020	Pagani, I. S., Dang, P., Saunders, V. A., Grose, R., Shanmuganathan, N., Kok, C. H., . . . Ross, D. M. (2020). Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia, 34(4), 1052-1061. DOI Scopus37 WoS29 Europe PMC21
2019	Tavakoli Shirazi, P., Eadie, L. N., Heatley, S. L., Hughes, T. P., Yeung, D. T., & White, D. L. (2019). The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.. British journal of cancer, 122(4), 455-464. DOI Scopus6 WoS6 Europe PMC5
2019	Forgione, M. O., McClure, B. J., Eadie, L. N., Yeung, D. T., & White, D. L. (2019). KMT2A rearranged acute lymphoblastic leukaemia: unravelling the genomic complexity and heterogeneity of this high-risk disease. Cancer Letters, 469, 410-418. DOI Scopus27 WoS22 Europe PMC15
2019	Ross, D. M., Pagani, I. S., Irani, Y. D., Clarson, J., Leclercq, T., Dang, P., . . . Yong, A. S. M. (2019). Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology, 186(3), e56-e60. DOI Scopus10 WoS7 Europe PMC7
2019	Kok, C. H., Yeung, D. T., Lu, L., Watkins, D. B., Leclercq, T. M., Dang, P., . . . Hughes, T. P. (2019). Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances, 3(10), 1610-1621. DOI Scopus25 WoS24 Europe PMC21
2018	Ross, D., Pagani, I., Shanmuganathan, N., Kok, C., Seymour, J., Mills, A., . . . Hughes, T. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia, 32(12), 2572-2579. DOI Scopus59 WoS46 Europe PMC32
2018	Page, E. C., Heatley, S. L., Yeung, D. T., Thomas, P. Q., & White, D. L. (2018). Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients. Cancer Letters, 432, 69-74. DOI Scopus5 WoS4 Europe PMC3
2018	Branford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., . . . Hughes, T. P. (2018). Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood, 132(9), 948-961. DOI Scopus136 WoS121 Europe PMC95
2018	Lu, L., Kok, C. H., Saunders, V., Wang, J., McLean, J., Hughes, T. P., . . . White, D. L. (2018). Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines. Oncotarget, 9(78), 34735-34747. DOI Scopus14 Europe PMC5
2018	Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., . . . Ross, D. M. (2018). BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica, 103(12), 2026-2032. DOI Scopus29 WoS20 Europe PMC16
2018	Eadie, L. N., Hughes, T. P., & White, D. L. (2018). Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia, 32(10), 2288-2291. DOI Scopus10 WoS10 Europe PMC4
2018	Nair, S. S., Luu, P. -L., Qu, W., Maddugoda, M., Huschtscha, L., Reddel, R., . . . Clark, S. J. (2018). Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. Epigenetics & Chromatin, 11(1), 24. DOI Scopus33 WoS27 Europe PMC24
2018	Eadie, L., Dang, P., Goyne, J., Hughes, T., & White, D. (2018). ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE, 13(1), e0192180-1-e0192180-18. DOI Scopus18 WoS13 Europe PMC13
2018	Eadie, L., Saunders, V., Branford, S., White, D., & Hughes, T. (2018). The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget, 9(17), 13423-13437. DOI Scopus36 Europe PMC19
2018	McClure, B., Heatley, S., Kok, C., Sadras, T., An, J., Hughes, T., . . . White, D. (2018). Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. British Journal of Cancer, 118(7), 1000-1004. DOI Scopus29 WoS25 Europe PMC20
2017	Pagani, I. S., Kok, C. H., Saunders, V. A., Van der Hoek, M. B., Heatley, S. L., Schwarer, A. P., . . . Ross, D. M. (2017). A method for next-generation sequencing of paired diagnostic and remission Samples to detect mitochondrial DNA mutations associated with leukemia. The Journal of molecular diagnostics : JMD, 19(5), 711-721. DOI Scopus6 WoS5 Europe PMC5
2017	Sadras, T., Heatley, S., Kok, C., McClure, B., Yeung, D., Hughes, T., . . . White, D. (2017). A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genetics, 216-217, 86-90. DOI Scopus10 WoS9 Europe PMC8
2017	Sadras, T., Heatley, S., Kok, C., Dang, P., Galbraith, K., McClure, B., . . . White, D. (2017). Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters, 408, 92-101. DOI Scopus18 WoS18 Europe PMC14
2017	Heatley, S. L., Sadras, T., Kok, C. H., Nievergall, E., Quek, K., Dang, P., . . . White, D. L. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica, 102(12), e490-e493. DOI Scopus49 WoS44 Europe PMC25
2017	Eadie, L., Hughes, T., & White, D. (2017). Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'. Leukemia, 31(3), 769-770. DOI
2017	Eadie, L. N., Dang, P., Saunders, V. A., Yeung, D. T., Osborn, M. P., Grigg, A. P., . . . White, D. L. (2017). The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia, 31(1), 75-82. DOI Scopus51 WoS51 Europe PMC38
2017	Sopper, S., Mustjoki, S., White, D., Hughes, T., Valent, P., Burchert, A., . . . Wolf, D. (2017). Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology, 35(2), 175-184. DOI Scopus32 WoS25 Europe PMC17
2017	Barratt, D., Cox, H., Menelaou, A., Yeung, D., White, D., Hughes, T., & Somogyi, A. (2017). CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clinical Pharmacokinetics, 56(8), 977-985. DOI Scopus19 WoS17 Europe PMC11
2017	Hughes, A., Clarson, J., Tang, C., Vidovic, L., White, D., Hughes, T., & Yong, A. (2017). CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood, 129(9), 1166-1176. DOI Scopus136 WoS122 Europe PMC88
2017	Banjar, H., Ranasinghe, D., Brown, F., Adelson, D., Kroger, T., Leclercq, T., . . . Chaudhri, N. (2017). Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia. PLoS ONE, 12(1), 1-23. DOI Scopus4 WoS3 Europe PMC3
2017	Wang, J., Lu, L., Kok, C., Saunders, V., Goyne, J., Dang, P., . . . White, D. (2017). Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica, 102(5), 843-853. DOI Scopus10 WoS11 Europe PMC4
2016	Trahair, T., Lock, R., Sutton, R., Sia, K., Evans, K., Richmond, J., . . . Revesz, T. (2016). Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL. Bone Marrow Transplantation, 51(9), 1279-1282. DOI Scopus5 WoS5 Europe PMC4
2016	Lopes, B., Meyer, C., Barbosa, T., Stadt, U., Horstmann, M., Venn, N., . . . Emerenciano, M. (2016). COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia. Oncotarget, 7(33), 53064-53073. DOI Scopus9 WoS9 Europe PMC6
2016	Eadie, L., Hughes, T., & White, D. (2016). ABCB1 Overexpression Is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines. PLoS ONE, 11(8), e0161470-1-e0161470-18. DOI Scopus33 WoS26 Europe PMC23
2016	White, D. (2016). Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant. Cancer Research, 76(15), 4579-4591. DOI Scopus18 WoS17 Europe PMC12
2016	Dolai, S., Sia, K., Robbins, A., Zhong, L., Heatley, S., Vincent, T., . . . Lock, R. (2016). Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia. Cancer Research, 76(9), 2766-2777. DOI Scopus12 WoS13 Europe PMC9
2016	Latham, S., Bartley, P., Budgen, B., Ross, D., Hughes, E., Branford, S., . . . Morley, A. (2016). BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. Journal of Clinical Pathology, 69(9), 817-821. DOI Scopus9 WoS9 Europe PMC5
2016	Nievergall, E., Reynolds, J., Kok, C., Watkins, D., Biondo, M., Busfield, S., . . . White, D. (2016). TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia, 30(6), 1263-1272. DOI Scopus38 WoS32 Europe PMC23
2016	Sadras, T., D'Andrea, R., & White, D. (2016). The Role of Wnt/β -Catenin Signaling in Normal and Malignant Hematopoiesis, Hemostasis. J Blood Res Hematol Dis, 1(1), 1-9. DOI
2015	Yeung, D., Tang, C., Vidovic, L., White, D., Branford, S., Hughes, T., & Yong, A. (2015). KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. Blood, 126(25), 2720-2723. DOI Scopus25 WoS22 Europe PMC18
2015	Watkins, D., Hughes, T., & White, D. (2015). OCT1 and imatinib transport in CML: Is it clinically relevant?. Leukemia, 29(10), 1960-1969. DOI Scopus47 WoS40 Europe PMC25
2015	White, D. L., & Hughes, T. P. (2015). Living with CML: Is death no longer the end (point)?. Blood, 126(1), 2-4. DOI WoS1 Europe PMC5
2015	Yeung, D., Moulton, D., Heatley, S., Nievergall, E., Dang, P., Braley, J., . . . White, D. (2015). Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia, 29(1), 230-232. DOI Scopus24 WoS20 Europe PMC13
2015	Yeung, D., Osborn, M., White, D., Branford, S., Braley, J., Herschtal, A., . . . Hughes, T. (2015). TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923. DOI Scopus79 WoS67 Europe PMC46
2015	Bartley, P., Latham, S., Budgen, B., Ross, D., Hughes, E., Branford, S., . . . Morley, A. (2015). A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. The Journal of Molecular Diagnostics, 17(2), 185-192. DOI Scopus20 WoS16 Europe PMC10
2015	Lu, L., Saunders, V., Leclercq, T., Hughes, T., & White, D. (2015). Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia, 29(8), 1792-1794. DOI Scopus20 WoS22 Europe PMC16
2015	Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., Leclercq, T., Hughes, T., & White, D. (2015). Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia, 29(1), 76-85. DOI Scopus28 WoS27 Europe PMC23
2014	Kok, C. H., Leclercq, T., Watkins, D. B., Saunders, V., Wang, J., Hughes, T. P., & White, D. L. (2014). Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. Leukemia, 28(3), 702-705. DOI Scopus5 WoS4 Europe PMC5
2014	Roberts, K., Li, Y., Payne-Turner, D., Harvey, R., Yang, Y., Pei, D., . . . Mullighan, C. (2014). Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New England Journal of Medicine, 371(11), 1005-1015. DOI Scopus1056 WoS927 Europe PMC732
2014	Eadie, L., Hughes, T., & White, D. (2014). Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clinical Pharmacology & Therapeutics, 95(3), 294-306. DOI Scopus66 WoS60 Europe PMC47
2014	Nievergall, E., Ramshaw, H., Yong, A., Biondo, M., Busfield, S., Vairo, G., . . . Hiwase, D. (2014). Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood, 123(8), 1218-1228. DOI Scopus83 WoS77 Europe PMC62
2014	Dolai, S., Sia, K. C. S., Robbins, A. K., Zhong, L., Heatley, S., Vincent, T., . . . Lock, R. B. (2014). Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling. BLOOD, 124(21), 3 pages.
2013	Grinfeld, J., Gerrard, G., Alikian, M., Alonso-Dominguez, J., Ale, S., Valagnon, M., . . . Foroni, L. (2013). A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. British Journal of Haematology, 163(5), 631-639. DOI Scopus33 WoS30 Europe PMC22
2013	Ross, D., Branford, S., Seymour, J., Schwarer, A., Arthur, C., Yeung, D., . . . Hughes, T. (2013). Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122(4), 515-522. DOI Scopus599 WoS542 Europe PMC424
2013	Kok, C., Watkins, D., Leclercq, T., D'Andrea, R., Hughes, T., & White, D. (2013). Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation. Leukemia, 27(6), 1427-1430. DOI Scopus11 WoS12 Europe PMC11
2013	Hiwase, D., Saunders, V., Nievergall, E., Ross, D., White, D., & Hughes, T. (2013). Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells. Haematologica, 98(6), 896-900. DOI Scopus8 WoS9 Europe PMC7
2013	White, D., Eadie, L., Saunders, V., Hiwase, D., & Hughes, T. (2013). Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia, 27(5), 1201-1204. DOI Scopus7 WoS7 Europe PMC6
2013	Watkins, D., Hughes, T., White, D., & D'Andrea, R. (2013). NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis. Leukemia, 27(2), 489-490. DOI Scopus11 WoS8 Europe PMC8
2013	Eadie, L., Saunders, V., Hughes, T., & White, D. (2013). Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leukemia & Lymphoma, 54(3), 569-578. DOI Scopus24 WoS21 Europe PMC21
2013	Schafranek, L., Leclercq, T., White, D., & Hughes, T. (2013). Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. Leukemia & Lymphoma, 54(1), 198-201. DOI Scopus26 WoS21 Europe PMC16
2013	Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., White, D., Hughes, T., & Leclercq, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner. Blood, 122(21), 2705. DOI WoS1
2013	Hughes, T., & White, D. (2013). Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology, 2013(1), 168-175. DOI Scopus43 WoS37 Europe PMC26
2013	Angelini, S., Soverini, S., Ravegnini, G., Barnett, M., Turrini, E., Thornquist, M., . . . Martinelli, G. (2013). Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica, 98(2), 193-200. DOI Scopus88 WoS85 Europe PMC65
2012	White, D. L., Brown, A. L., D'Andrea, R. J., & Rice, A. M. (2012). Unraveling the "known unknowns": lessons and reflections from the new directions in leukemia research 2012 conference. Cancer Research, 72(17), 4300-4303. DOI
2012	White, D., Radich, J., Soverini, S., Saunders, V., Frede, A., Dang, P., . . . Hughes, T. (2012). Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica, 97(6), 907-914. DOI Scopus50 WoS45 Europe PMC35
2012	Wang, J., Hughes, T., Kok, C., Saunders, V., Frede, A., Groot Obbink, K., . . . White, D. (2012). Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. British Journal of Cancer, 106(11), 1772-1778. DOI Scopus19 WoS18 Europe PMC15
2012	White, D., & Hughes, T. (2012). Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. Journal of Clinical Oncology, 2012(10), 1144-1145. DOI Scopus14 WoS9 Europe PMC8
2011	Esposito, N., Colavita, I., Quintarelli, C., Sica, A., Peluso, A., Luciano, L., . . . Pane, F. (2011). SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood, 118(13), 3634-3644. DOI Scopus46 WoS40 Europe PMC35
2011	Tang, C., Schafranek, L., Watkins, D., Parker, W., Moore, S., Prime, J., . . . Hughes, T. (2011). Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leukemia & Lymphoma, 52(11), 2139-2147. DOI Scopus50 WoS46 Europe PMC36
2011	Hiwase, D., Yeung, D., & White, D. (2011). Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. Expert Review of Hematology, 4(3), 285-299. DOI Scopus6 WoS6 Europe PMC5
2011	Engler, J., Hughes, T., & White, D. (2011). OCT-1 as a determinant of response to antileukemic treatment. Clinical Pharmacology & Therapeutics, 89(4), 608-611. DOI Scopus10 WoS9 Europe PMC7
2011	Engler, J., Zannettino, A., Bailey, C., Rasko, J., Hughes, T., & White, D. (2011). OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica: the haematology journal, 96(2), 1-33. DOI Scopus13 WoS12 Europe PMC11
2011	Yeung, D. T., & White, D. L. (2011). Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?. Leukemia and Lymphoma, 52(2), 165-167. DOI
2011	White, D., & Hughes, T. (2011). Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current Hematologic Malignancy Reports, 6(2), 88-95. DOI Scopus7 WoS7 Europe PMC6
2010	White, D. L., Saunders, V. A., Dang, P., Engler, J., & Hughes, T. P. (2010). OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia, 24(11), 1962-1965. DOI Scopus36 WoS34 Europe PMC24
2010	Engler, J., Frede, A., Saunders, V., Zannettino, A., White, D., & Hughes, T. (2010). The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells. Blood, 116(15), 2776-2778. DOI Scopus20 WoS18 Europe PMC12
2010	Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. (2010). Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?. Journal of Clinical Endocrinology and Metabolism, 95(8), 3763-3767. DOI Scopus50 WoS46 Europe PMC41
2010	Hiwase, D., White, D., Powell, J., Saunders, V., Zrim, S., Frede, A., . . . Hughes, T. (2010). Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia, 24(4), 771-778. DOI Scopus48 WoS42 Europe PMC33
2010	White, D., Dang, P., Engler, J., Frede, A., Osborn, M., Saunders, V., . . . Hughes, T. (2010). Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with Imatinib. Journal of Clinical Oncology, 28(16), 2761-2767. DOI Scopus157 WoS142 Europe PMC111
2010	Eadie, L., Hughes, T., & White, D. (2010). Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia, 24(4), 855-857. DOI Scopus9 WoS8 Europe PMC8
2010	Engler, J., Frede, A., Saunders, V., Zannettino, A., Hughes, T., & White, D. (2010). Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity. Leukemia, 24(4), 765-770. DOI Scopus55 WoS52 Europe PMC40
2010	Hiwase, D., White, D., Zrim, S., Saunders, V., Vaz de Melo, J., & Hughes, T. (2010). Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia, 24(3), 658-660. DOI Scopus26 WoS25 Europe PMC22
2009	White, D., & Hughes, T. (2009). Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current Hematologic Malignancy Reports, 4(2), 59-65. DOI Scopus6 Europe PMC5
2009	Hiwase, D., White, D., Saunders, V., Kumar, S., Melo, J., & Hughes, T. (2009). Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL<sup>+</sup> cells. Leukemia, 23(6), 1205-1206. DOI Scopus16 WoS15 Europe PMC11
2008	Hughes, T. P., Branford, S., White, D. L., Reynolds, J., Koelmeyer, R., Seymour, J. F., . . . Grigg, A. (2008). Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CMLpatients receiving 600 mg/day of imatinib as initial therapy. Blood, 112(10), 3965-3973. DOI Scopus145 WoS135 Europe PMC116
2008	Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888. DOI Scopus164 WoS145 Europe PMC121
2008	Mullighan, C., Miller, C., Radtke, I., Philips, L., Dalton, J., Ma, J., . . . Downing, J. (2008). BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 453(7191), 110-114. DOI Scopus857 WoS783 Europe PMC662
2008	White, D. L. (2008). Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?. Leukemia and Lymphoma, 49(6), 1022-1023. DOI
2007	White, D., Saunders, V., Dang, P., Engler, J., Venables, A., Zrim, S., . . . Hughes, T. (2007). Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 110(12), 4064-4072. DOI Scopus277 WoS255 Europe PMC196
2007	White, D., Saunders, V., Grigg, A., Arthur, C., Filshie, R., Leahy, M., . . . Hughes, T. (2007). Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. Journal of Clinical Oncology, 25(28), 4445-4451. DOI Scopus54 WoS52 Europe PMC48
2007	White, D., Saunders, V., Quinn, S., Manley, P., & Hughes, T. (2007). Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugs. Blood, 109(8), 3609-3610. DOI Scopus40 WoS44 Europe PMC29
2006	White, D., Saunders, V., Dang, P., Engler, J., Zannettino, A., Cambareri, A., . . . Hughes, T. (2006). OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 108(2), 697-704. DOI Scopus383 WoS322 Europe PMC253
2005	White, D., Saunders, V., Lyons, A., Branford, S., Grigg, A., To, L., & Hughes, T. (2005). In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de-novo CML.. Blood, 106(7), 2520-2526. DOI Scopus124 WoS109 Europe PMC90
2003	Roberts, M., Dyson, P., Rawling, C., Thorp, D., Rawling, T., White, D., . . . Hughes, T. (2003). Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD. Cytotherapy, 5(6), 534-541. DOI Scopus2 WoS2 Europe PMC2
2003	Hui, C., Goh, K., White, D., Branford, S., Grigg, A., Seymour, J., . . . Hughes, T. (2003). Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia, 17(5), 821-828. DOI Scopus40 WoS33 Europe PMC26
2000	Hughes, T., White, D., Bresatz, S., Forte, M., Lewis, I., & Lyons, A. (2000). Normal and leukemic engraftment in the nod/scid mouse model. Haematologica, 85, 10-11.
1997	White, D., Hutchins, C., Turczynowicz, S., Suttle, J., Haylock, D., Hughes, T., . . . To, L. (1997). Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish. Pathology, 29(3), 289-293. DOI Scopus9 WoS10 Europe PMC7
1995	Kumar, S., White, D., Takai, S., Turczynowicz, S., Juttner, C., & Hughes, T. (1995). Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7934-35, a region frequently affected in haematological neoplasms. Human Genetics, 95(6), 641-644. DOI Scopus40 WoS38 Europe PMC23
1995	White, D., Hutchins, C., Haylock, D., Turczynowics, S., Bishop, A., To, L., . . . Juttner, C. (1995). A direct analysis of FACS-sorted hemopoietic cell fractions using fish. Biotechniques, 18(5), 818-821. Scopus4 WoS3
1994	HUGHES, T. P., WHITE, D. L., HAYLOCK, D. N., TURCZYNOWICZ, S., HUTCHINS, C. J., TO, L. B., & JUTTNER, C. A. (1994). CYTOKINE SUPPORTED CULTURE OF CD34+ CELLS FROM AML PATIENTS RESULTS IN EXPANSION OF BOTH LEUKEMIC AND NORMAL PROGENITORS. BLOOD, 84(10), A52. WoS1
1989	HUTCHINS, C., CASEY, G., WHITE, D., MOORE, S., RUDZKI, Z., & KIMBER, R. (1989). DETECTION OF REARRANGEMENT WITHIN THE BREAKPOINT CLUSTER REGION OF CHROMOSOME 22 IN THE DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA. Australian and New Zealand Journal of Medicine, 19(5), 443-448. DOI
1987	White, D. L., Ashman, L. K., Dart, G. W., Zola, H., Toogood, I. R. G., & Kimber, R. J. (1987). The expression of mature myeloid cell differentiation markers in acute leukemia. Pathology, 19(2), 137-142. DOI Scopus10 WoS12 Europe PMC5
1987	Ashman, L. K., White, D., Zola, H., & Dart, G. W. (1987). Expression of the non-T ALL-associated p24 antigen on leukaemic blasts from patients with ANLL. Leukemia Research, 11(1), 97-101. DOI Scopus5 WoS8 Europe PMC6

Conference Papers

Year	Citation
2023	White, D. L., Rehn, J. A., Schutz, C. E., Heatley, S. L., Eadie, L. N., Thomson, A., . . . Greenwood, M. (2023). Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies. In BLOOD Vol. 142 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI
2023	Eadie, L. N., Schutz, C. E., Page, E. C., Conlin, T. S., Heatley, S. L., Lagonik, E., . . . White, D. L. (2023). Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI
2022	Poudel, G., Yeung, D. T., White, D. L., Hughes, T., & Pagani, I. S. (2022). <i>PTPN11</i> Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph plus ALL Cells, but Are Sensitive to the Combination. In BLOOD Vol. 140 (pp. 3128-3129). LA, New Orleans: AMER SOC HEMATOLOGY. DOI
2021	Page, E. C., Heatley, S. L., Rehn, J., Yeung, D. T., Thomas, P. Q., & White, D. L. (2021). <i>HMGN1</i> expression Predisposes Down Syndrome Patients to Develop <i>P2RY8-CRLF2</i> acute Lymphoblastic Leukemia. In BLOOD Vol. 138 (pp. 4 pages). Atlanta, GA: AMER SOC HEMATOLOGY. DOI
2020	Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020 (2020). In HemaSphere Vol. 4 (pp. 1-1168). Wiley. DOI
2018	Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins. DOI
2018	Chan, L. N., Shojaee, S., Hurtz, C., Auer, F., Chen, Z., Cosgun, K. N., . . . Muschen, M. (2018). Divergent Evolutionary Trajectories of Erkand Stat5-Activating Lesions in Acute Lymphoblastic Leukemia. In BLOOD Vol. 132 (pp. 2 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI
2018	Yeung, D. T., Grigg, A. P., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2018). Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. In BLOOD Vol. 132 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS5
2017	Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood Vol. 130 (pp. 1597). Atlanta: American Society of Hematology.
2016	Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group.
2016	Asari, K., Heatley, S. L., Sadras, T., Leclercq, T. M., Fitter, S., Kok, C. H., . . . White, D. L. (2016). <i>In Vitro</i> Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance Implications for Targeted Therapy. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI
2016	Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . Hughes, T. P. (2016). Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI
2016	Zaliova, M., Moorman, A. V., Cazzaniga, G., Stanulla, M., Harvey, R. C., Roberts, K. G., . . . Zuna, J. (2016). Characterization of leukemias with ETV6-ABL1 fusion. In Proceedings of the 57th Annual Meeting of the American-Society-of-Hematology, as published in Haematologica Vol. 101 (pp. 1082-1093). Orlando, FL: Ferrata Storti Foundation. DOI Scopus61 WoS44 Europe PMC39
2016	Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. M. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
2016	Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). MODELLING PONATINIB RESISTANCE IN BCR-ABL1+CELL LINES: IMPLICATIONS FOR PONATINIB THERAPY. In HAEMATOLOGICA Vol. 101 (pp. 182-183). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
2015	Eadie, L. N., Hughes, T. P., & White, D. L. (2015). The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS1
2015	Kok, C. H., Leclercq, T. M., Watkins, D., Yeung, D. T., Saunders, V. A., White, D. L., & Hughes, T. P. (2015). A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2015	Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2015	Wang, J., Kok, C. H., Leclercq, T. M., Saunders, V. A., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2015). High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγle) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2014	Eadie, L. N., Hughes, T. P., & White, D. L. (2014). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to over TKI resistance. In NDLR Abstract Handbook Vol. 122 (pp. 2 pages). Noosa, QLD: AMER SOC HEMATOLOGY. DOI
2013	White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. In Blood Vol. 122 (pp. 256). American Society of Hematology. DOI
2013	Eadie, L., Hughes, T. P., & White, D. L. (2013). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to overt TKI resistance. In Blood Vol. 122 (pp. 5157). New Orleans, Louisiana: American Society of Hematology. DOI
2013	Gordon, J. E. A., Bailey, C. G., Rasko, J., Ritchie, W., Watkins, D. B., White, D. L., . . . Hughes, T. P. (2013). MicroRNA Dysregulation in Newly Diagnosed Chronic Myeloid Leukaemia Patients. In BLOOD Vol. 122 (pp. 1 page). New Orleans, LA: AMER SOC HEMATOLOGY. DOI
2011	White, D. L., Saunders, V. A., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. P. (2011). The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients. In BLOOD Vol. 118 (pp. 735). San Diego, CA: AMER SOC HEMATOLOGY.
2011	Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY. WoS1
2011	Watkins, D. B., Kok, C. H., Hughes, T. P., Slader, C., D'Andrea, R., & White, D. L. (2011). Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. In BLOOD Vol. 118 (pp. 727). San Diego, CA: AMER SOC HEMATOLOGY.
2011	Nievergall, E., White, D. L., Ramshaw, H., Lopez, A. F., Hughes, T. P., & Hiwase, D. K. (2011). Antibody-Targeting of IL-3 Receptor-α Increases the Susceptibility of CD34<SUP>+</SUP> CML Progenitors to Dasatinib-Induced Cell Death. In BLOOD Vol. 118 (pp. 1599). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1
2011	Wang, J., Hughes, T. P., Kok, C. H., Saunders, V. A., Frede, A., GrootObbink, K., . . . White, D. L. (2011). Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy. In BLOOD Vol. 118 (pp. 1493-1494). San Diego, CA: AMER SOC HEMATOLOGY.
2011	White, D. L., Lu, L., Clackson, T. P., Saunders, V. A., & Hughes, T. P. (2011). ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib. In BLOOD Vol. 118 (pp. 1180). San Diego, CA: AMER SOC HEMATOLOGY. WoS1
2010	Soverini, S., Angelini, S., Turrini, E., Burnett, M., Ravegnini, G., Thornquist, M., . . . Martinelli, G. (2010). Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib - A TOPS Correlative Substudy. In BLOOD Vol. 116 (pp. 293-294). Orlando, FL: AMER SOC HEMATOLOGY.
2010	Tang, C., Schafranek, L., Watkins, D., Parker, W. T., Prime, J., White, D. L., & Hughes, T. (2010). Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression. In BLOOD Vol. 116 (pp. 1385). Orlando, FL: AMER SOC HEMATOLOGY.
2010	White, D. L., Saunders, V., Andrew, M., Rofe, A., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Imatinib PK: Observations From the TIDEL II Study.. In BLOOD Vol. 116 (pp. 943). Orlando, FL: AMER SOC HEMATOLOGY.
2010	White, D. L., Saunders, V., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study. In BLOOD Vol. 116 (pp. 160-161). Orlando, FL: AMER SOC HEMATOLOGY.
2010	Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS10
2010	Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida.
2010	Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology. DOI
2010	Hiwase, D. K., Engler, J., Saunders, V., White, D. L., & Hughes, T. (2010). In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34<SUP>+</SUP> Progenitors Is Not Significantly Different Than That Observed In CD34<SUP>-</SUP> Mature Cells.. In BLOOD Vol. 116 (pp. 517). Orlando, FL: AMER SOC HEMATOLOGY.
2010	Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY. WoS1
2009	Osborn, M. P., Branford, S., White, D. L., Seymour, J. F., Columbus, R., Taylor, K., . . . Hughes, T. P. (2009). Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.. In BLOOD Vol. 114 (pp. 461-462). New Orleans, LA: AMER SOC HEMATOLOGY.
2009	Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S., Frede, A., . . . Hughes, T. (2009). Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. In BLOOD Vol. 114 (pp. 1258-1259). New Orleans, LA: AMER SOC HEMATOLOGY.
2009	White, D. L., Saunders, V. A., Frede, A., Dang, P., Zrim, S., Osborn, M. P., . . . Hughes, T. (2009). The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial. In BLOOD Vol. 114 (pp. 209-210). New Orleans, LA: AMER SOC HEMATOLOGY.
2009	Osborn, M. P., White, D. L., Saunders, V. A., Cambareri, B., Branford, S., Menelaou, A., . . . Hughes, T. P. (2009). Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.. In BLOOD Vol. 114 (pp. 465). New Orleans, LA: AMER SOC HEMATOLOGY.
2009	Soverini, S., Angelini, S., Turrini, E., Pane, F., Quarantelli, F., Hughes, T. P., . . . Martinelli, G. (2009). Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity. In BLOOD Vol. 114 (pp. 1271). New Orleans, LA: AMER SOC HEMATOLOGY.
2009	Engler, J. R., Frede, A., Saunders, V. A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2009). OCT-1 Activity in CML CD34+Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity. In BLOOD Vol. 114 (pp. 861). New Orleans, LA: AMER SOC HEMATOLOGY.
2008	Hiwase, D. K., White, D. L., Saunders, V. A., Melo, J. V., Kumar, S., & Hughes, T. P. (2008). Short-Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+Cells Unless They Are Growth Factor Deprived. In BLOOD Vol. 112 (pp. 397). San Francisco, CA: AMER SOC HEMATOLOGY.
2008	Engler, J. R., Frede, A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2008). Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. In BLOOD Vol. 112 (pp. 80). San Francisco, CA: AMER SOC HEMATOLOGY. WoS2
2008	Esposito, N., Quarantelli, F., Luciano, L., Izzo, B., Peluso, A. L., Picardi, M., . . . Pane, F. (2008). The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial. In BLOOD Vol. 112 (pp. 404). San Francisco, CA: AMER SOC HEMATOLOGY.
2008	Mullighan, C. G., Radtke, I., Zhang, J., Phillips, L. A., Su, X., Ma, J., . . . Downing, J. R. (2008). Genome-Wide Analysis of Genetic Alterations in Chronic Myelogenous Leukemia. In BLOOD Vol. 112 (pp. 397-398). San Francisco, CA: AMER SOC HEMATOLOGY. WoS6
2008	White, D. L., Saunders, V. A., Kalebic, T., & Hughes, T. P. (2008). The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients. In BLOOD Vol. 112 (pp. 405). San Francisco, CA: AMER SOC HEMATOLOGY. WoS1
2008	White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In BLOOD Vol. 112 (pp. 1093-1094). San Francisco, CA: AMER SOC HEMATOLOGY. WoS3
2008	White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In Blood Vol. 112 (pp. 3187). American Society of Hematology. DOI
2007	Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology. DOI
2007	Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY. WoS7
2005	White, D. L., Saunders, V. A., Engler, J., Dang, P., Zannettino, A. C., Cambareri, A., . . . Hughes, T. P. (2005). Low baseline intrinsic sensitivity to imatinib (high IC50) in CML patients is due to reduced Oct-1 mediated influx. Intrinsic sensitivity to AMN107 does not correlate with that of imatinib and uptake of AMN107 is not Oct-1 mediated.. In BLOOD Vol. 106 (pp. 315A). Atlanta, GA: AMER SOC HEMATOLOGY.
2005	White, D. L., Saunders, V. A., Branford, S., Lynch, K., To, L. B., & Hughes, T. P. (2005). The in-vivo level of imatinib induced kinase inhibition achieved in de-novo CML patients during the first 28 days of therapy is a powerful predictor of molecular outcome.. In BLOOD Vol. 106 (pp. 132A). Atlanta, GA: AMER SOC HEMATOLOGY.
2004	White, D. L., Saunders, V. A., Branford, S., Lyons, B., & Hughes, T. P. (2004). The combination of intrinsic sensitivity to imatinib and Sokal prognostic score is strongly predictive of molecular response in newly diagnosed CML patients treated with imatinib.. In BLOOD Vol. 104 (pp. 288A-289A). San Diego, CA: AMER SOC HEMATOLOGY.

Conference Items

Year	Citation
2022	Thomson, A., Rehn, J., Heatley, S., Eadie, L., McClure, B., Page, E., . . . White, D. (2022). Benchmarking the detection rate of IGH gene fusions in B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) Conference.
2021	Heatley, S. L., Page, E. C., Eadie, L. N., McClure, B. J., Rehn, J., Yeung, D. T., . . . White, D. L. (2021). Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI
2021	Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 4th International T-ALL/T-NHL conference: T-ALL2020: Omics, genetics and therapy.
2021	McClure, B., Heatley, S., Grose, R., & White, D. (2021). Activation of the immune cell repertoire in B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS).
2021	Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS).
2021	Heatley, S., Rehn, J., Breen, J., Moore, A., Sutton, R., Osborn, M., & White, D. (2021). Using single cell mRNAseq to interrogate the genomic consequences of Ph-like acute lymphoblastic leukaemia in adolescents. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS).
2020	Poudel, G., Yeung, D., White, D., Hughes, T., & Pagani, I. (2020). Understanding the mechanisms of imatinib resistance in a Ph+ acute lymphoblastic leukaemia cell line. Poster session presented at the meeting of The 59th ASMR National Scientific Conference.
2020	Page, E., Heatley, S., Thomas, P., & White, D. (2020). HMGN1 is necessary for Down Syndrome leukaemic cell proliferation and cooperates with CRLF2 for leukaemic transformation. Poster session presented at the meeting of The 59th ASMR National Scientific Conference.
2020	Eadie, L., Heatley, S., McClure, B., Schutz, C., Breen, J., Hughes, T., . . . White, D. (2020). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group.
2020	McClure, B., Heatley, S., Grose, R., Yeung, D., & White, D. (2020). Activation of the immune cell repertoire in B-cell acute lymphoblastic leukaemia.. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group.
2020	Page, E., Heatley, S., Thomas, P., & White, D. (2020). Inducible Knockout of HMGN1 in an In Vivo xenograft Model Reduces Down Syndrome Leukemic Burden and Increases Survival Outcomes. Poster session presented at the meeting of 62nd ASH ANNUAL MEETING AND EXPOSITION.
2020	Downes, C. E. J., McClure, B. J., Rehn, J., Breen, J., Bruning, J. B., Yeung, D. T., & White, D. L. (2020). Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an <i>in Vitro</i> model of a High-Risk Acute Lymphoblastic Leukemia. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: AMER SOC HEMATOLOGY. DOI WoS1
2020	Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Schutz, C. S., Breen, J., . . . White, D. L. (2020). Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: AMER SOC HEMATOLOGY. DOI WoS1
2020	Tavakoli, P., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent Activation of JAK/STAT Signaling Plays an Important Role in<i>in Vitro</i>Jaki Resistance in <i>TYK2</i>-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: AMER SOC HEMATOLOGY. DOI
2020	Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib. Poster session presented at the meeting of 25th Congress of The European Hematology Association. Frankfurt, Germany (virtual meeting).
2020	Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Targeted pseudo-alignment technique for rapid and accurate identification of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of 14th Annual Florey Postgraduate Conference. Adelaide, South Australia.
2020	Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT.
2020	Forgione, M. O., McClure, B. J., Eadie, L. N., & White, D. L. (2020). CD44 and its ligand osteopontin are upregulated specifically in KMT2A-AFF1 T-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia.
2020	Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). Vorinostat treatment demonstrated efficacy against MYB-TYK2 altered B-cell acute lymphoblastic leukaemia in in vitro and in vivo models. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia.
2020	Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent activation of JAK/STAT signaling plays an important role in in vitro Jaki resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of 62nd Annual Meeting of the American Society of Hematology. San Diego, California (virtual conference).
2019	Page, E. C., Heatley, S. L., Yeung, D. T., Thomas, P. Q., & White, D. L. (2019). A Novel Role for <i>HMGN1</i> in Down Syndrome Acute Lymphoblastic Leukemia. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI
2019	Yeung, D. T., Shanmuganathan, N., Grigg, A., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2019). Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2
2019	Yeung, D. T., Grigg, A., Shanmuganathan, N., Solterbeck, A. C., White, D. L., Branford, S., . . . Hughes, T. P. (2019). Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI
2019	El Khawanky, N., Hughes, A., Yu, W., Taromi, S., Clarson, J., Lopez, A. F., . . . Zeiser, R. (2019). Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS4
2019	Cario, G., Leoni, V., Conter, V., Attarbaschi, A., Zaliova, M., Sramkova, L., . . . Biondi, A. (2019). Poor Prognosis in Children with ABL-Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI
2019	Tavakoli, P. S., Eadie, L., Heatley, S. L., & White, D. L. (2019). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting 2019. Christchurch, New Zealand.
2019	Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of 1st European Society of Haematology (ESH) Translational Conference on ALL. Berlin, Germany.
2019	Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia.
2019	Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L., Schutz, C. E., . . . White, D. L. (2019). Investigating “alignment-free” computational techniques for the accurate identification of Acute Lymphoblastic Leukaemia (ALL) gene fusion events. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia.
2019	Heatley, S. L., McClure, B. J., Eadie, L. N., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia.
2019	Yeung, D., Greenwood, M., Rehn, J., Heatley, S., McClure, B., Eadie, L., . . . White, D. (2019). High risk genomic alterations identified at the time of diagnosis are strongly associated with MRD and subsequent poor outcomes in AYA ALL patients treated on a pediatric inspired chemotherapy regimen. Poster session presented at the meeting of Blood. Orlando, CA: American Society of Hematology. DOI
2018	Downes, C., McClure, B., & White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. Poster session presented at the meeting of Childhood Leukaemia and Lymphoma Symposium. Helsinki, Finland.
2018	Asari, K., Leclercq, T., Srihari, S., Fitter, S., Yeung, D., Hughes, T., . . . White, D. L. (2018). in vitro modelling of Ph-like ALL uncovers novel genomic alterations associated with TKI-resistance as a consequence of targeted therapy. Poster session presented at the meeting of Childhood Leukaemia and Lymphoma Symposium. Helsinki, Finland.
2018	Heatley, S. L., Mayne, B. T., McClure, B. J., Kok, C., Sadras, T., Dang, P., . . . White, D. L. (2018). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of 23rd Congress of European Hematology Association. Stockholm, Sweden.
2018	Downes, C. E., McClure, B. J., Heatley, S. L., Yeung, D. T., & White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. Poster session presented at the meeting of NDLR.
2018	Heatley, S. L., McClure, B. J., Kok, C., Sadras, T., Dang, P., Galbraith, K., . . . White, D. L. (2018). Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing. Poster session presented at the meeting of NDLR.
2018	Pagani, I. S., Kok, C., Saunders, V., Schwarer, A., Hughes, T. P., White, D. L., & Ross, D. M. (2018). Association of mitochondrial DNA (mtDNA) mutations at diagnosis with treatment response in chronic myeloid leukaemia (CML) patients. Poster session presented at the meeting of NDLR.
2018	Eadie, L. N., Mullighan, C., & White, D. L. (2018). Mutations to the transcription factor MYB alter cellular localization and decrease degradation likely enhancing oncogenicity in patients with T-cell ALL. Poster session presented at the meeting of NDLR.
2018	Lu, L., Kok, C., Saunders, V., Nievergall, E., White, D. L., & Hughes, T. P. (2018). TGF-α predicts TKI treated CML patients who fail to achieve early molecular response. Poster session presented at the meeting of NDLR.
2018	Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of APG Student Awards.
2018	Page, E. C., Heatley, S. L., Thomas, P., & White, D. L. (2018). Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of ASMR.
2018	Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk JAK2 fusion in B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR.
2018	Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of ASMR.
2018	Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and Characterisation of Ruxolitinib Resistant Mutations in JAK2-rearranged B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of AGTA.
2018	Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of mutations that cause ruxolitinib resistance in Pro-B cells driven by a high-risk B-ALL JAK2-fusion.. Poster session presented at the meeting of ANZCHOG.
2018	Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of SAHMRI Scientific Seminar.
2018	Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of SAHMRI Scientific Seminar.
2018	Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of 12th Annual Florey postgraduate Conference.
2018	Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium.
2018	Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium.
2018	Osborn, M., Dalla-Pozza, L., Trahair, T., Sutton, R., White, D. L., Fleming, S., & Greenwood, M. (2018). The Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 Trial: A Phase II Study of Blinatumomab as Induction Therapy in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukaemia (ALL).. Poster session presented at the meeting of Global AYA Cancer Congress.
2017	El-Khawanky, N., Hughes, A., Yu, W., Clarson, J., Lopez, A. F., Brown, M., . . . Yong, A. (2017). CD123 Chimeric Antigen Receptor T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of HAA.
2017	El-Khawanky, N., Hughes, T. P., Clarson, J., Yu, W., White, D. L., & Yong, A. (2017). Anti-CD123 Chimeric Antigen Receptor (CAR) T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of ASMR.
2017	McClure, B. J., Heatley, S. L., Kok, C., Sadras, T., An, J., Quek, K., . . . White, D. L. (2017). EP300-ZNF384 is a recurrent fusion gene with distinct gene expression in adolescent/young adult pre-B-ALL patients. Poster session presented at the meeting of ANZCHOG.
2017	Heatley, S. L., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. L. (2017). High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk-Adapted Treatment. Poster session presented at the meeting of ANZCHOG.
2017	Asari, K., Sadras, T., Srihari, S., Fitter, S., An, J., Zannettino, A. C., . . . White, D. L. (2017). in vitro Modelling of Ph-like ALL Fusions Uncovers Novel Kinase-domain Mutations as a Mode of TKI-resistance and Potential Consequence of Targeted TKI Therapy. Poster session presented at the meeting of ANZCHOG.
2017	McClure, B. J., Heatley, S. L., Sadras, T., Sutton, R., & White, D. L. (2017). EP300-ZNF384 is a recurrent fusion gene with distinct gene expression in adolescent/young adult Australian pre-B-acute lymphoblastic leukaemia. Poster session presented at the meeting of IBFM.
2017	Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A., Filshie, R., . . . Hughes, T. P. (2017). Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Poster session presented at the meeting of 59th ASH Annual Meeting & Exposition.
2017	Hughes, A., Clarson, J., White, D. L., Yeung, D., Hughes, T. P., & Yong, A. S. M. (2017). Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. WoS4
2017	Yeung, D., Grigg, A., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2017). Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
2017	Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J., Saunders, V. A., Prime, J. A., . . . Ross, D. M. (2017). COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT: AN ALLG CML9 SUB-STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Madrid, SPAIN: FERRATA STORTI FOUNDATION.
2017	Downes, C. E., McClure, B. M., Heatley, S. H., Sadras, T. S., Hughes, T. H., Kok, C. K., . . . White, D. W. (2017). Identification and cloning of a novel GOLGA4-JAK2 fusion from an adult patient with B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster session presented at the ASMR SA Scientific Meeting. Adelaide.
2017	Heatley, S., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Poster session presented at the meeting of Abstracts of the 57th Annual Meeting of the American Society of Hematology, as published in Blood. Orlando, FL: American Society of Hematology. DOI WoS2
2016	Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I., . . . White, D. (2016). HIGH GENE EXPRESSION OF HIST1H2AG AND HIST1H4A REDUCES IMATINIB UPTAKE INTO CML CELLS AND PREDICTS POOR RESPONSE TO FRONTLINE IMATINIB THERAPY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
2016	Heatley, S., Sadras, T., kok, C., Venn, N., Revesz, T., Osborn, M., . . . White, D. L. (2016). Australian Children with Ph-like ALL enrolled to ANZCHOG ALL8 had a high prevalence of relapse despite risk adapted treatment. Poster session presented at the meeting of CLS SCIENTIFIC PROGRAMME, Refractory Leukemia and Miscellaneous. Athens.
2016	Lock, R., Dollai, S., Sia, K., Daly, R., Rafferty, M., White, D. L., . . . Revesz, T. (2016). Quantitative Phosphotyrosine Profiling of patient derived xenografts identifies therapeutic targets in paediatric ALL. Poster session presented at the meeting of .. Athens.
2016	Sadras, T., Heatley, S., Dang, P., Kok, C., Quek, K., Nievergall, E., . . . White, D. L. (2016). A nine-gene signature defines 2 groups of CRLF2 rearranged B-ALL patients with distinctive genetic features. Poster session presented at the meeting of .. Athens.
2016	Pagani, I. S., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . Ross, D. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia. Poster session presented at the meeting of .. Barcelona, Spain.
2016	Eadie, L., Saunders, V., Branford, S., Hughes, T., & White, D. (2016). Resistance mechanisms of the new allosteric inhibitor ABL001. Poster session presented at the meeting of ,. Houtson, USA.
2016	Eadie, L., Goyne, J., Hughes, T., & White, D. (2016). ABCC6 plays a significant role in the transport of nilotinib in both cells lines and primary patient cells, and may contribute to resistance. Poster session presented at the meeting of ,. Houston, USA.
2016	Saunders, V. A., Wang, J., Lu, L., Eadie, L. N., McLean, J. A., Goyne, J. M., . . . Hughes, T. P. (2016). A Low Concentration of ABL001 Potentiates <i>In Vitro</i> TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1
2016	Eadie, L. N., Goyne, J., Hughes, T., & White, D. L. (2016). The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance. Poster session presented at the meeting of .. San Diego, USA: AMER SOC HEMATOLOGY. DOI
2016	Eadie, L., Hughes, T., & White, D. (2016). ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment. Poster session presented at the meeting of Abstract presented at the New Directions in Leukaemia Research 2016 Meeting. Noosa, QLD.
2016	Eadie, L., Saunders, V., Leclercq, T., Branford, S., White, D. L., & Hughes, T. (2016). Abl001 Is Susceptible To Resistance Mediated By Overexpression Of Drug Transporters Abcb1 and Abcg2. Poster session presented at the meeting of .. Noosa, QLD.
2016	Sadras, T., Heatley, S., Kok, C., Quek, K., Dang, P., Nievergall, E., . . . White, D. L. (2016). CRLF2 rearranged B-ALL cases with a Ph-like gene signature are enriched for JAK2 mutations. Poster session presented at the meeting of .. Noosa, QLD.
2016	Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). Modelling ponatinib resistance in BCR-ABL1+ cell lines: implications for ponatinib therapy. Poster session presented at the meeting of New Directions in Leukaemia Research 2016. Noosa, QLD.
2016	McClure, B., Heatley, S., Sadras, T., Nievergall, E., Kok, C., Dang, P., . . . White, D. L. (2016). Identification of a significantly high prevalence of relapse in Australian children with Ph-like ALL. Poster session presented at the meeting of .. Noosa, QLD.
2016	Asari, K., Heatley, S., Leclercq, T., Fitter, S., Zannettino, A., Hughes, T., & White, D. L. (2016). In vitro Modelling of Therapeutic Resistance to Elucidate Mechanisms of TKI-Resistant High-Risk ALL. Poster session presented at the meeting of .. Noosa, QLD.
2016	Pagani, I., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . White, D. L. (2016). Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukemic clone?. Poster session presented at the meeting of .. Noosa, QLD.
2016	Eadie, L., Dang, P., Saunders, V., Hughes, T., & White, D. L. (2016). The clinical significance of early imatinib induced ABCB1 overexpression in chronic phase CML patients treated sequentially with imatinib and nilotinib: A TIDEL II sub-study. Poster session presented at the meeting of ,. Adelaide, SA.
2016	White, D. L., McClure, B., Heatley, S., Sadras, T., Quek, K., & Hughes, T. (2016). Investigation of the transforming capacity of a recently identified EP300-ZNF384 fusion gene in adult acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA.
2016	Leow, B., Eadie, L. N., Leclercq, T., & White, D. L. (2016). Drug resistance in CML: heterogeneity, selection, and clonal architecture. Poster session presented at the meeting of Poster Session. Adelaide, SA.
2016	Asari, K., Heatley, S., Leclercq, T., Fitter, S., Kok, C. H., Zannettino, A., . . . White, D. L. (2016). Investigating Modes of Therapeutic Resistance via In Vitro Modelling of TKI-resistant High-Risk Philadelphia-chromosome-positive and Philadelphia-chromosome-like Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA.
2016	Galbraith, K., Sadras, T., McClure, B., Heatley, S., & White, D. L. (2016). Identification of novel therapeutic targets in CRLF2 rearranged acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA.
2016	Watts, S., Saunders, V., Wee, A., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Understanding the mechanism of secondary resistance to Azacitidine in Myelodysplastic syndromes using the cell-line model MOLM-13. Poster session presented at the meeting of Poster Session. Adelaide, SA.
2016	Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I. S., . . . White, D. L. (2016). High Gene Expression of hist1h2ag and hist1h4a Reduces Imatinib Uptake into CML Cells and Predicts Poor Response to Frontline Imatinib Therapy. Poster session presented at the meeting of Poster Session. Melbourne, VIC.
2016	Heatley, S., Sadras, T., McClure, B., Kok, C. H., Dang, P., Nievergall, E., . . . White, D. L. (2016). The Incidence of Ph-like Acute Lymphoblastic Leukaemia (ALL) Increases with Age and is Characterised by Poor Outcome. Poster session presented at the meeting of Poster Session. Melbourne, VIC.
2016	Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Van der Hoek, M., Heatley, S., . . . Ross, D. (2016). Mitochondrial DNA Mutations at Diagnosis are Linked to Response in TKI treated Chronic Myeloid Leukaemia Patients. Poster session presented at the meeting of Poster Session. Melbourne, VIC.
2016	Watts, S., Wee, A., Saunders, V., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Determining Mechanisms of Resistance to Azacitidine (Aza) in Myelodysplastic (MDS) Syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model. Poster session presented at the meeting of Poster Session. Melbourne, VIC.
2016	Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T., & White, D. L. (2016). Modelling Ponatinib Resistance In BCR-ABL1+ Cell Lines: Implications For Ponatinib Therapy. Poster session presented at the meeting of Poster Session. Adelaide, SA.
2016	Hughes, A., Clarson, J., White, D. L., Ross, D. M., Hughes, T. P., & Yong, A. S. (2016). Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS6
2015	Zaliova, M., Moorman, A., Cazzaniga, G., Stanulla, M., Harvey, R., Roberts, K., . . . Zuna, J. (2015). Characterization of Leukemias with ETV6-ABL1 Fusion. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
2014	Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T. P., & White, D. L. (2014). Modeling Ponatinib Resistance in <i>BCR-ABL1</i>+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naive Patients. Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY.
2014	Yeung, D. T., Vidovic, L., Tang, C., White, D. L., Branford, S., Hughes, T. P., & Yong, A. S. M. (2014). KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY.
2014	Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology. DOI WoS1
2014	Parker, W. T., Phillis, S. R., Yeung, D. T., Lawrence, D., Schreiber, A., Wang, P., . . . Branford, S. (2014). Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. DOI WoS4
2013	White, D. L., Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D., Leclercq, T., & Hughes, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a Bcr-Abl-dependent, but JAK2-independent manner.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA.
2013	White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of <i>In Vivo</i> Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY. WoS1
2013	Wang, J., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2013). Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY. DOI
2013	White, D. L., Eadie, L., & Hughes, T. (2013). Increasing Expression of the Efflux Transporter ABCB1 may Predispose CML Cells to Overt TKI Resistance.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA.
2012	White, D. L., Saunders, V., Yeung, D., Grigg, A., & Hughes, T. (2012). Early Molecular Response to Imatinib in CP-CML Patients: The Significance of Early Dose Intensity and OCT-1 Activity in Responders and Efficacy of Dose Escalation and Switch to Nilotinib in Non-Responders.. Poster session presented at the meeting of American Society of Haematology. Atlanta, USA.
2012	Watkins, D. B., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2012). Global DNA methylation analysis identifies key pathway differences between poor (low OCT-1 activity) and standard risk CP-CML patients at diagnosis. Poster session presented at the meeting of “Abstracts of the 54th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood. Atlanta, GA: America Society of Hematology.
2012	Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS8
2012	Nievergall, E., White, D. L., Yong, A. S. M., Ramshaw, H. S., Busfield, S. J., Vairo, G., . . . Hiwase, D. K. (2012). Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI
2012	Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., White, D. L., & Hughes, T. P. (2012). Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS3

Theses

Year Citation
2017 Downes, C. E. (2017). Cloning, Signalling Characterisation and JAK2 Inhibitor-Resistance of Two JAK2 Fusions in High-Risk B-ALL. (Undergraduate Dissertation).

Year	Citation
2017	Downes, C. E. (2017). Cloning, Signalling Characterisation and JAK2 Inhibitor-Resistance of Two JAK2 Fusions in High-Risk B-ALL. (Undergraduate Dissertation).

Peer Reviewed Research Funding

I have been successful in securing competitive research funding (Approx $30million).

International Competitive Schemes LLS (CML. 2009 and 2016) and the Hughes Foundation/USC Parker Institute (ALL 2015, 2016) NHMRC (2007 (CML),2009(CML), 2012(CML), 2012 (ALL), 2013(CML),and 2014(CML), Leukaemia Foundation of Australia (LFA) (2008 2012 (CML) and 2013 (ALL)), Cancer Council of SA (2011 (CML) and 2012 (ALL) and Channel 7 2015 (ALL). NHMRC TCR in genomics now (AGHA)(ALL $25 million). A significant outcome of the work of my group has been the successful translation into clinical practice. In excess of $5.5 million in Pharmaceutical funding over the last 10 years has been secured.

International Peer Reviewed Competitive Schemes

First Year Funded	Agency	Title	Applicant Role	Amount
2016	Leukemia Lymphoma Society of the USA (LLS)	Developing a bioassay-based algorithm for selecting frontline therapy in chronic myeloid leukemia	Timothy Hughes, CIB:Deborah L White, Gerald Radich, David Yeung, Chung Kok and John Reynolds	$US600,000.00
2015	USC Parker Institute for Childhood Cancer Research Incorporating the William Lawrence and Blanche Hughes Foundation	Identification of mechanisms of drug resistance in paediatric models of Ph-like ALL treated with targeted therapies	CIA Deborah White CIB- Charles Mullighan	$US450,000.00
2009	Leukemia Lymphoma Society of the USA (LLS)	The role of OCT-1 Activity enhancers in improving the response of patients with low OCT-1 activity to Imatinib	Deborah L White, Timothy Hughes, Richard D’Andrea, Andrew Somogyi and Junia Melo	$US600,000.00

National Peer Reviewed Competitive Schemes (Other than NHMRC)

2019	Leukaemia Foundation	Precision Medicine in Acute Lymphoblastic Leukaemia	Deborah White, Laura Eadie	$250,000.00
2019	Tour de Cure – Senior Research Grant	Acute Lymphoblastic Leukaemia: Understanding the factors that determine response to new immune-based therapies.	Deborah White, David Lynn and Gerraint Rogers	$100,000.00
2019	Tour de Cure – Pioneering Grant	Reducing the toxicity associated with agonistic antibody cancer immunotherapies by targeting the gut microbiota	Steven Blake, David Lynn and Deborah White	$50,000.00
2019	Beat Cancer Project – Principal Research Fellowship	Precision Medicine in Acute Lymphobastic Leukaemia	Deborah White	$600,000.00
2018	Australian Cancer Research Fund (ACRF)	INFRASTRUCTURE: Australian Cancer Research Foundation Centre for Integrated Cancer Systems Biology (ACRFCICSB)	CIs: Hughes, Zannettino, White, Proud, Wesselingh, Lynn, Butler, Gronthos, Tilley, Price, Worthley, Bulone	$2,500,000.00
2018	Beat Cancer Project - Infrastructure Grant	INFRASTRUCTURE: A Bioinformatician for the Joint SAHMRI/AHMRI Bioinformatics Core	Deborah White	$234,000.00
2018	Flinders Foundation	The role of the gut microbiota in the efficacy and toxicity of agonistic antibody cancer immunotherapies	Lynn D., Blake S. & White D	$22,890.00
2017	Cancer Australia	Improving outcomes for high risk ALL treated with new therapies and transplant.	Rosemary Sutton, Deborah White, Toby Trahair, Peter Shaw	$600,000.00
2017	Tour de Cure	Rapid Identification of High Risk Subtypes & Targeted Treatments for Children with Acute Lymphoblastic Leukaemia	Toby Trahair, Rosemary Sutton, Glenn Marshall, Draga Barbaric, Luciano Dalla Pozza, Deborah White	$200,000.00
2017	Australian Research Council (ARC): LIEF Scheme	INFRASTRUCTURE: Adelaide Flow Cytometry Facility.	Robertson, McColl, Zannettino, Tyreman, Thompson, Mitchell, Brown, McKinnon, Hayball, Cowin, Makridis, White	$480,000.00
2017	Australian Federal Government	INFRASTRUCTURE: Zero Childhood Cancer	CI White (SA and SAHMRI Lead)	$20,000,000.00 (Received $1,479,303.00)
2017	Anthony Rothe Memorial Trust	Better Outcomes for Child & Adolescent ALL Project.	Toby Trahair, Marion Mateos, Glenn Marshall, David Ziegler, Rosemary Sutton, Rishi Kotecha, Siobhan Cross, Deborah White	$200,000.00
2016	PG16-01 Cancer Council NSW Program Grant	Improving outcomes for children with leukaemia through molecular targeted therapies	AI: White	$800,000.00
2016	Channel 7 Children’s Research Foundation	High-Risk T cell ALL	Laura Eadie and Deborah White	$75,000.00
2016	Kids Cancer Project	Single cell genomics in high-risk ALL	Susan Heatley and Deborah White	$176,000.00
2016	Beat Cancer Infrastructure Grant	INFRASTRUCTURE: Transforming research into improved heatlh for patients with Leukaemia	Deborah White	$90,000.00
2015	Channel 7 Children’s Research Foundation	Developing a robust screening tool to identify children with high risk “Ph-like” Acute Lymphoblastic Leukaemia (ALL) that will lead to improved outcomes through the use of targeted therapies	Susan Heatley, Deborah White, Charles Mullighan	$75,000.00
2013	Australian Cancer Research Fund (ACRF)	INFRASTRUCTURE: Cancer Imaging and Therapeutics Facility	CIs: Mullighan, Hughes, White, Zannettino, Gronthos, Keefe, Monro, Roder, Tilley, Price.	$1,800,000.00
2013	Leukaemia Foundation Australia	Childhood Ph-like ALL: Improving Diagnostic Screening and Therapeutic Rationale	Deborah White and Prof Charles Mullighan	$100,000.00
2012	SA Cancer Research Collaborative	INFRASTRUCTURE: Establishing the SA Biospecimen Respository	Deborah L White (CIE)	$980,000.00
2012	Beat Cancer Project Grant	Assessing the cause and drug susceptibility of Adult high-risk ALL	Deborah L White, Charles Mullighan and Timothy P Hughes	$80,000.00
2012	Leukaemia Foundation Australia	Characterisation of immune responses in CML patients on nilotinib and interferon alpha	Yong, A, Hughes, T and White DL	$100,000.00
2012	Leukaemia Foundation Australia	Developing a gene signature to predict the optimal front line kinase inhibitor for CP-CML patients	Deborah White and Prof Timothy Hughes	$99,254.00
2011	Cancer Council of South Australia	Developing a patient specific approach to the treatment of CP-CML with tyrosine kinase inhibitors: investigating the factors which determine response to nilotinib and dasatinib	Deborah White, Richard D’Andrea, Timothy Hughes, John Rasko, Junia Vaz de Melo	$92,508.00

NHMRC Schemes (peer reviewed) (>$13 million)

2019	NHMRC Fellowship	Setting a new Paradigm for Diagnosis and Therapeutic Triage in ALL using Functional Genomics	Deborah White	$483,404.00
2017	NHMRC Project Grant	Chronic myeloid leukaemia: changing the treatment paradigm	CI’s: Hughes, Ross, Branford, White, Yong, and Reynolds	$1,162,778.08
2016	Targeted Call for Research (TCR)	Genomics Translation: Preparing Australia for Genomic Medicine: A Proposal by the Australian Genomics Health Alliance (AGHA)	Chief Investigator White(ALL Australian Flagship Lead Investigator)	$25,000,000.00 (Received $1,250,000.00)
2015	NHMRC Program Grant	Aberrant Signalling in Leukaemia	CI’s: A. Lopez, T Hughes, M Parket AI: White, D	$6,669,345.00
2014	NHMRC Project Grant	Determining the prerequisites for the achievement of treatment-free remission in chronic myeloid leukaemia to facilitate the development of new therapeutic approaches with curative intent	CIA: Timothy Hughes, CIB: Deborah White, CIC: Susan Branford, CID:David Ross, CIE:Agnes Yong	$1,400,000.00
2013	NHMRC Project Grant	Screening and targeting newly discovered genetic lesions in poor risk adult and childhood ALL	CIA Deborah White, CIB Charles Mullighan, CIC Timothy Hughes, CID Rosemary Sutton	$718,892.85
2012	NHMRC Project Grant	Characterisation of a New Poor-Risk Sub-Category of Chronic Phase Chronic Myeloid Leukaemia	CIA Deborah White, CIB Tim Hughes, CIC Richard D’Andrea	$588,675.00
2012	NHMRC Project Grant	Rational development of a bioassay-based treatment algorithm for kinase inhibitor therapy in CML	CIA Timothy Hughes, CIB Deborah White, CIC John Rasko	$509,880.00
2009	NHMRC Project Grant	Development and assessment of novel assays to predict response to second-line TKI therapy in imatinib resistant CML	CIA:Timothy Hughes, CIB: Junia Melo, CIC:Susan Branford, CID: Deborah L White	$485,000.00

Industry Funding - Granted (>$5.5 million)

2015	Bristol Myers Squibb	Correlative Science Proposal Associated with the DIRECT study	Deborah White, David Yeung & Timothy Hughes	$598,000.00
2015	Bristol Myers Squibb	Correlative Science Proposal Associated with the REGALLIA Clinical Registry	Deborah White, David Yeung & Timothy Hughes	$902,965.00
2015	Celgene	Correlative Science Proposal Associated with the LENI	David Ross, Timothy Hughes, Deborah Whiteand Agnes Yong	$440,000.00
2014	Novartis Pharmaceuticals Australia	Correlative Science Proposal Associated with the ENESTswift clinical trial	Deborah White, Devendra Hiwase, Agnes Yong	$500,000.00
2014	Novartis Pharmaceuticals Australia	Correlative Science Proposal Associated with the PINNACLE clinical trial	Deborah White, Susan Branford, Agnes Yong, David Yeung	$675,000.00
2012	Bristol Myers Squibb	Correlative Science Proposal Associated with the ALL06 clinical trial	Deborah White	$94,560.00
2011	Novartis Pharmaceuticals Australia	Provision of imatinib OCT-1 Activity testing for newly diagnosed CML patients	Deborah White	$155,925.00
2011	Novartis Pharmaceuticals Australia	Correlative Science Proposal Associated with the ENESTxtnd clinical trial	Deborah White	$698,255.68
2011	Novartis Pharmaceuticals Australia	Correlative Science Associated with TIDELII Clinical Trial - expansion of patient numbers	Deborah White and Timothy Hughes	$65,971.00
2011	Australasian Leukaemia and Lymphoma Group	Seed Funding: Investigating the Prevalence of Druggable Novel Gene Fusion, Detectable by Phospho-Flow Analysis in High Risk Adult B-ALL	Deborah White, Timothy Hughes and Charles Mullighan	$20,880.00
2010	Bristol Myers Squibb	RESIST Registry	Timothy Hughes and Deborah White	$920,000.00
2010	Novartis Pharmaceuticals Australia	Correlative Science Associated with TIDELII Clinical Trial Cohort 2	Deborah White and Timothy Hughes	$659,707.91
2009	Bristol Myers Squibb	Correlative Science Proposal Associated with the Ph+ ALL- Dasatinib clinical trial.	Deborah White and Andrew Grigg	$154,919.00

Local Schemes- Granted

2017	Contributing Haematologists Committee Research Grants	Evaluate role of cellular influx and efflux pumps in Azacitidine	Devendra Hiwase, Sophie Watts, Verity Saunders, Timothy Hughes, Deborah White and Amilia Wee	$25,000.00
2017	Contributing Haematologists Committee Research Grants	Functional effects of mitochondrial mutations in CML	David Ross and Deborah White, Ilaria Pagani and Timothy Hughes	$25,000.00
2016	Contributing Haematologists Committee Research Grants	Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukaemic clone	David Ross and Deborah White	$25,000.00
2016	Contributing Haematologists Committee Research Grants	Identification of mechanisms of drug resistance in models of Ph-like ALL treated with targeted therapies	David Yeung, Sue Heatley, Tessa Sadras, Tim Hughes, Deborah White	$25,000.00
2015	Contributing Haematologists Committee Research Grants	Digital PCR for BCR-ABL DNA in chronic myeloid leukaemia	David Ross and Deborah White	$30,000.00
2014	Contributing Haematologists Committee Research Grants	Mitochondrial mutations in chronic myeloid leukaemia.	David Ross and Deborah White	$30,000.00

Undergraduate Lectures

Guest Lecturer CML Biology 3^rd Year Health and Biotech, University of SA

Guest Lecturer 3^rd Year Pharmacology

Guest Lecturer 3^rd Year Biomedical Science

Guest lecture series Final Year Advanced Biomedical Science + associated tutorials

Project Mentor to third year MBBS students; Research Project Design: ALL

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2024	Principal Supervisor	Identifying Predictors of CNS involvement in Acute Lymphoblastic Leukaemia	Doctor of Philosophy	Doctorate	Full Time	Mr Luke Jacob Quinlan
2024	Principal Supervisor	Clinical Transcriptomic Sequencing Analysis Workflows for Acute Lymphoblastic Leukaemia (ALL): Improving Subtype Characterisation in Complex Fusion Events	Doctor of Philosophy	Doctorate	Full Time	Miss Ashlee Jean Thomson
2023	Co-Supervisor	Modelling co-occurring mutations in T-cell Acute Lymphoblastic Leukaemia to enhance treatment options and maximise the power of next generation sequencing	Doctor of Philosophy	Doctorate	Full Time	Mr Maxim Jon Buckley
2023	Co-Supervisor	Discovery of novel metabolic targets against lDH1-mutant intrahepatic cholangiocarcinoma	Doctor of Philosophy	Doctorate	Full Time	Mrs Tasnova Tasnim Nova
2023	Principal Supervisor	Interrogating the DUX4 rearranged subtype of B cell Acute Lymphoblastic Leukaemia	Doctor of Philosophy	Doctorate	Full Time	Mr Thomas Oliver McGovern
2023	Principal Supervisor	Exploring the impact of the gut microbiota on the clinical scenario in Acute Lymphoblastic Leukaemia patients	Doctor of Philosophy	Doctorate	Full Time	Miss Cate Viktorija Cheney
2022	Principal Supervisor	Characterisation of a novel fusion, genetic contributors and effectiveness of drug combinations in Ph-like Acute Lymphoblastic Leukaemia and the clinical relevance.	Doctor of Philosophy	Doctorate	Full Time	Jane Frances Thompson
2022	Co-Supervisor	A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery	Doctor of Philosophy	Doctorate	Full Time	Miss Maha Kamel
2021	Principal Supervisor	Investigation of current, innovative treatments and the roles of secondary genomic lesions in BCR-ABL1 positive leukaemias	Doctor of Philosophy	Doctorate	Full Time	Mr Elias Lagonik

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2019 - 2022	Principal Supervisor	Characterising KMT2A and MLLT10 Rearranged Acute Lymphoblastic Leukaemia	Doctor of Philosophy	Doctorate	Full Time	Miss Michelle Olivia Forgione
2019 - 2023	Co-Supervisor	Bioinformatic approaches to variant detection and subtype classification in acute lymphoblastic leukaemia	Doctor of Philosophy	Doctorate	Full Time	Miss Jacqueline Ann Rehn
2018 - 2021	Principal Supervisor	Exploring the cooperation and targetability of CRLF2 and HMGN1 in Down Syndrome Acute Lymphoblastic Leukaemia	Doctor of Philosophy	Doctorate	Full Time	Miss Elyse Chenae Page
2018 - 2022	Principal Supervisor	Precision Medicine Approaches for JAK2-Rearranged Acute Lymphoblastic Leukaemia: The Efficacy of Targeted Therapies and Molecular Mechanisms of Drug Resistance	Doctor of Philosophy	Doctorate	Full Time	Miss Charlotte Emma-Jeane Downes
2017 - 2021	Principal Supervisor	Characterising the novel MYB-TYK2 fusion gene in high-risk acute lymphoblastic leukaemia: oncogenic potential, effective therapeutic strategies and In vitro modelling of drug resistance mechanisms	Doctor of Philosophy	Doctorate	Full Time	Miss Paniz Tavakoli Shirazi
2016 - 2021	Principal Supervisor	The Combined Treatment Efficacy of Anti-CD123 CAR T cells with Azacitidine for the Treatment of Acute Myeloid Leukaemia.	Doctor of Philosophy under a Jointly-awarded Degree Agreement with	Doctorate	Full Time	Miss Nadia El-Khawanky
2015 - 2019	Principal Supervisor	Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors In Chronic Myeloid Leukaemia	Doctor of Philosophy	Doctorate	Full Time	Mr Benjamin Chia Sing Leow
2014 - 2018	Principal Supervisor	In vitro Modelling of High-risk ALL Fusions Uncovers Genomic Alterations and Non-canonical Signalling Pathways as a Mode of TKI-Resistance - Implications for Targeted Therapy	Doctor of Philosophy	Doctorate	Full Time	Miss Kartini Asari
2012 - 2016	Principal Supervisor	In Vitro Investigation of Intracellular Ponatinib Transport and Modeling Ponatinib Resistence in BCR-ABL1+ Cell Lines: Implications for Therapeutic Strategies	Doctor of Philosophy	Doctorate	Full Time	Miss Liu Lu
2012 - 2014	Co-Supervisor	The role of cytokines in governing the expansion of the T315I mutation in Chronic myeloid leukaemia	Master of Philosophy (Medical Science)	Master	Full Time	Dr Oi-Lin Lee
2012 - 2018	Co-Supervisor	Personalized Medicine Support System for Chronic Myeloid Leukaemia Patients	Doctor of Philosophy	Doctorate	Full Time	Mrs Haneen Reda M Banjar
2010 - 2014	Co-Supervisor	Assessment of Critical Survival Mechanisms Exploited by BCR-ABL1+ Cells to Evade Tyrosine Kinase Inhibitor-Induced Death; Determination of Novel Therapeutic Targets in Chronic Myeloid Leukaemia	Doctor of Philosophy	Doctorate	Full Time	Miss Lisa Schafranek
2010 - 2014	Principal Supervisor	Defining CP-CML patient subsets associated with poor imatinib uptake and response	Doctor of Philosophy	Doctorate	Full Time	Mr Dale Benjamin Watkins
2009 - 2013	Co-Supervisor	Nilotinib Efflux and Resistance Development: The Effects of Combination and Concomitant Therapies on the Transport and Efficacy of Nilotinib	Doctor of Philosophy	Doctorate	Full Time	Ms Laura Eadie
2008 - 2012	Co-Supervisor	TKI Resistance in CML Cell Lines: Investigating Resistance Pathways	Doctor of Philosophy	Doctorate	Full Time	Mrs Carine Tang
2008 - 2011	Co-Supervisor	Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia	Doctor of Philosophy	Doctorate	Full Time	Ms Jane Engler
2008 - 2010	Co-Supervisor	Evaluation of Anti-proliferative and Pro-apoptotic Effects of Tyrosine Kinase Inhibitors on CML-CD34+ Cells	Doctor of Philosophy	Doctorate	Full Time	APrf Devendra Hiwase
2008 - 2013	Co-Supervisor	Investigating Drugs that Enhance Imatinib Uptake and Factors which Contribute to the Functional Activity of OCT-1 in CML Cells	Doctor of Philosophy	Doctorate	Full Time	Miss Jueqiong Wang

Board Memberships

Date	Role	Board name	Institution name	Country
2023 - ongoing	Member	South Australian Genomics Consortium (SAGC) Advisory Board	SAGC	Australia
2023 - ongoing	Director	Board of Directors Australian and New Zealand Children's Oncology Group (ANZCHOG)	ANZCHOG	Australia
2023 - ongoing	Director	Board of Directors Australasian Leukaemia Lymphomas Group (ALLG)	ALLG	Australia
2016 - ongoing	Member	Nuclear Fuel Cycle Royal Commission Consultation and Response Advisory (CARA) Board	-	-

Committee Memberships

Date	Role	Committee	Institution	Country
2017 - ongoing	Advisory Board Member	Australian and New Zealand Children's Hematology/ Oncology Group	-	Australia
2016 - ongoing	Chair	ALL Stream of Australian Genomics Health Care Alliance (AGHA)	-	-
2016 - ongoing	Chair	ALL Stream of the Australian Genomics Health Care Alliance (AHGA)	-	-
2016 - ongoing	Member	Australian Genomics Health Care Alliance (AHGA) Executive	-	-
2016 - ongoing	Member	Scientific Committee for the New Directions in Leukaemia Research Conference	-	-
2016 - ongoing	Chair	SAHMRI Genomics Executive Committee	-	-
2016 - ongoing	Chair	Women in Health Science Session	National Directions in Leukemia Research	Australia
2016 - ongoing	Chair	SAHMRI Imaging Workshop	South Australia Health and Medical Research Institute	-
2016 - ongoing	Chair	Post Graduate Student Forum	Basil Hetzel Institute Research Day	Australia
2016 - ongoing	Founder	SA Translational Cancer Research Group Meetings	-	Australia
2016 - ongoing	Founder	Statewide Cancer Translational Research Group	-	Australia
2016 - ongoing	Member	Scientific Symposium Committee	South Australian Health and Medical Research Institutesa	Australia
2015 - ongoing	Member	Women in Science Executive Committee	-	-
2015 - ongoing	Member	NHMRC Women in Health Science Faculty	-	-
2015 - ongoing	Member	National Women in Health Science Faculty	NHMRC	Australia
2015 - ongoing	Chair	Ross Wishart Memorial Award	Australian Society for Medical Research	Australia
2015 - ongoing	Chair	CML and Myelproliferative Neoplasms	HAA	-
2015 - ongoing	Member	US Ambassadors Round Table on Scientific Innovation	-	-
2015 - ongoing	Member	American Association for Cancer Research	-	United States
2014 - ongoing	Chair	Women in Science session	New Directions in Leukemia Research	Australia
2014 - 2016	Member	SAHMRI post graduate student Committee	-	-
2014 - 2015	Advisory Board Member	(Malignant Haematology) HAA Organising Committee	-	Australia
2014 - ongoing	Chair	Young Investigator session	New Directions in Leukemia Research	Australia
2014 - ongoing	Chair	Women in Science session	New Directions in Leukemia Research	Australia
2014 - ongoing	Member	SA Translational Haematology Research Group Meetings	-	-
2014 - ongoing	Member	Scientific Committee for the New Directions in Leukaemia Research Conference	-	-
2014 - ongoing	Member	International Chronic Myeloid Leukemia Foundation (iCMLf)	-	Australia
2014 - ongoing	Chair	CML and Myeloproliferative Neoplasm Session	New Directions in Leukemia Research	Australia
2013 - ongoing	Member	Biosciences Pillar Committee	-	-
2013 - ongoing	Member	Executive Management Committee	-	-
2013 - ongoing	Member	Research Executive Committee	-	-
2013 - ongoing	Member	BMS Advisory Board on Molecular Monitoring and Drug level Testing	-	-
2013 - 2015	Founder	Haematology Statewide Translational Research Group	-	-
2013 - ongoing	Member	International Children's Oncology Group	-	-
2012 - ongoing	Chair	ALL Stream of the Australian Genomics Health Care Alliance (AHGA)	-	Australia
2012 - ongoing	Member	• Member of the South Australian Cancer Collaborative (SACCC) Executive Committee	-	-
2012 - ongoing	Member	Bioscience Pillar Committee	South Australian Health and Medical Research Institute	Australia
2012 - ongoing	Member	Research Translational faculty	NHMRC	Australia
2012 - ongoing	Chair	Leukaemia Foundation Early Career Scientists Session	New Directions in Leukemia Research	-
2012 - ongoing	Member	SAHMRI Bioscience Pillar Committee	-	-
2012 - ongoing	Member	NHMRC Research Translational faculty	-	-
2012 - ongoing	Chair	Bioscience Pillar SA Comprehensive Cancer Consortium (SACCC)	-	-
2012 - ongoing	Chair	Myeloid Leukaemia Session	New Directions in Leukemia Research	Australia
2012 - ongoing	Member	New Directions in Leukemia Research Conference	-	-
2008 - ongoing	Member	Global Advisory Board Blood Level Testing and Mutational Analysis	Novartis	-
2008 - ongoing	Member	European Haematology Association	-	-
2008 - ongoing	Member	American Society of Haematology	-	United States
2008 - ongoing	Member	Haematology Association of Australia and New Zealand	-	Australia
2008 - ongoing	Member	Australian Leukemia and Lymphoma Group	-	Australia
2000 - ongoing	Member	The Australasian Leukaemia & Lymphoma Group Scientific Committee	-	-

Memberships

Date	Role	Membership	Country
2016 - ongoing	Member	Franklin Women	-
2015 - ongoing	Member	American Association for Cancer Research	-
2014 - ongoing	Member	International CML Foundation	-
2013 - ongoing	Member	International Children’s Oncology Group (COG)	-
2010 - ongoing	Member	Australian Leukaemia and Lymphoma Group: Laboratory Scientific Committee (only non-clinician invited)	-
2008 - ongoing	Member	Haematology Association of Australia and New Zealand	-
2008 - ongoing	Member	Australian Leukaemia and Lymphoma Group (ALLG)	-
2008 - ongoing	Member	European Haematology Association	-
2008 - ongoing	Member	American Society of Haematology	-

Consulting/Advisories

Date	Institution	Department	Organisation Type	Country
2016 - ongoing	Department of Premier and Cabinet	DPC and CARA	Legislative and political	Australia
2015 - ongoing	Sigma Aldrich: Science Next Collaborative	-	-	-
2013 - ongoing	BMS Advisory Board on Molecular Monitoring and Drug level Testing	-	-	-
2008 - ongoing	Novartis Global Advisory Board Blood Level Testing and Mutational Analysis	-	-	-

Editorial Boards

Date Role Editorial Board Name Institution Country
2016 - ongoing Associate Editor Journal of Blood Research & Hematologic Diseases - -

Date	Role	Editorial Board Name	Institution	Country
2016 - ongoing	Associate Editor	Journal of Blood Research & Hematologic Diseases	-	-

Position: Director, Cancer Program and Deputy Theme
Phone: 0881284302
Email: deborah.l.white@adelaide.edu.au
Campus: North Terrace
Building: SAHMRI, floor 5
Org Unit: Adelaide Medical School

Professor Deborah White

Appointments

Awards and Achievements

Education

Research Interests

Journals

Conference Papers

Conference Items

Theses

Peer Reviewed Research Funding

International Peer Reviewed Competitive Schemes

National Peer Reviewed Competitive Schemes (Other than NHMRC)

NHMRC Schemes (peer reviewed) (>$13 million)

Industry Funding - Granted (>$5.5 million)

Local Schemes- Granted

Current Higher Degree by Research Supervision (University of Adelaide)

Past Higher Degree by Research Supervision (University of Adelaide)

Board Memberships

Committee Memberships

Memberships

Consulting/Advisories

Editorial Boards

Connect With Me

External Profiles

Other Links